PDF(Pubmed)
Abstract：
BACKGROUND: The adjuvanted recombinant zoster vaccine (RZV), consisting of varicella-zoster virus glycoprotein E (gE) and the AS01B adjuvant system, effectively prevents herpes zoster (HZ). In the absence of a well-defined correlate of protection, it is important to monitor the RZV immune response, as a proxy of clinical effectiveness.
METHODS: This systematic review examined post-vaccination parameters: humoral and cell-mediated immunity, avidity index, geometric mean concentration of antibody (GMC), and immunity persistence. The meta-analysis used a random-effects model, and subgroup and meta-regression analyses were conducted.
RESULTS: Among 37 included articles, after one month from RZV-dose 2, the pooled response rate for anti-gE humoral immunity was 95.2% (95%CI 91.9-97.2), dropping to 77.6% (95%CI 64.7-86.8) during immunosuppression. The anti-gE cell-mediated immunity-specific response reached 84.6% (95%CI 75.2-90.9). Varying factors, such as age, sex, coadministration with other vaccines, prior HZ, or live-attenuated zoster vaccine, did not significantly affect response rates. RZV induced a substantial increase in gE avidity. Immunity persistence was confirmed, with more rapid waning in the very elderly.
CONCLUSIONS: This systematic review indicates that RZV elicits robust immunogenicity and overcomes immunocompromising conditions. The findings underscore the need for further research, particularly on long-term immunity, and have the potential to support HZ vaccination policies and programs.
METHODS: This systematic review examined post-vaccination parameters: humoral and cell-mediated immunity, avidity index, geometric mean concentration of antibody (GMC), and immunity persistence. The meta-analysis used a random-effects model, and subgroup and meta-regression analyses were conducted.
RESULTS: Among 37 included articles, after one month from RZV-dose 2, the pooled response rate for anti-gE humoral immunity was 95.2% (95%CI 91.9-97.2), dropping to 77.6% (95%CI 64.7-86.8) during immunosuppression. The anti-gE cell-mediated immunity-specific response reached 84.6% (95%CI 75.2-90.9). Varying factors, such as age, sex, coadministration with other vaccines, prior HZ, or live-attenuated zoster vaccine, did not significantly affect response rates. RZV induced a substantial increase in gE avidity. Immunity persistence was confirmed, with more rapid waning in the very elderly.
CONCLUSIONS: This systematic review indicates that RZV elicits robust immunogenicity and overcomes immunocompromising conditions. The findings underscore the need for further research, particularly on long-term immunity, and have the potential to support HZ vaccination policies and programs.
摘要：
背景：佐剂化重组带状疱疹疫苗（RZV），由水痘-带状疱疹病毒糖蛋白E（gE）和AS01B佐剂系统组成，有效预防带状疱疹（HZ）。在没有明确定义的保护关联的情况下，监测RZV免疫反应很重要，作为临床有效性的代表。
方法：本系统综述检查了疫苗接种后的参数：体液和细胞介导的免疫，亲和力指数,抗体的几何平均浓度（GMC），和免疫力的坚持。荟萃分析使用随机效应模型，进行亚组和meta回归分析.
结果：在37篇收录的文章中，从RZV剂量2开始一个月后，抗gE体液免疫的合并应答率为95.2％（95CI91.9-97.2），免疫抑制期间降至77.6%(95CI64.7-86.8)。抗gE细胞介导的免疫特异性应答达到84.6%(95CI75.2-90.9)。各种因素，比如年龄,性别,与其他疫苗联合使用，先前的HZ，或活减毒带状疱疹疫苗，没有显著影响应答率。RZV诱导gE亲和力的显著增加。免疫持久性得到证实，在非常年长的人中消失得更快。
结论:该系统评价表明RZV引发稳健的免疫原性并克服了免疫受损条件。这些发现强调了进一步研究的必要性，特别是在长期免疫方面，并有潜力支持HZ疫苗接种政策和计划。
方法：本系统综述检查了疫苗接种后的参数：体液和细胞介导的免疫，亲和力指数,抗体的几何平均浓度（GMC），和免疫力的坚持。荟萃分析使用随机效应模型，进行亚组和meta回归分析.
结果：在37篇收录的文章中，从RZV剂量2开始一个月后，抗gE体液免疫的合并应答率为95.2％（95CI91.9-97.2），免疫抑制期间降至77.6%(95CI64.7-86.8)。抗gE细胞介导的免疫特异性应答达到84.6%(95CI75.2-90.9)。各种因素，比如年龄,性别,与其他疫苗联合使用，先前的HZ，或活减毒带状疱疹疫苗，没有显著影响应答率。RZV诱导gE亲和力的显著增加。免疫持久性得到证实，在非常年长的人中消失得更快。
结论:该系统评价表明RZV引发稳健的免疫原性并克服了免疫受损条件。这些发现强调了进一步研究的必要性，特别是在长期免疫方面，并有潜力支持HZ疫苗接种政策和计划。
